Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999424 · ClinicalTrials.gov registry record · Phase 1
Autologous Human Schwann Cells in Peripheral Nerve Repair
A Phase 1 study, sponsored by W. Dalton Dietrich.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03999424 is a Phase 1 study that has completed, run by W. Dalton Dietrich. The registered enrollment target is 5 participants.
The verdict
NCT03999424, a Phase 1 study, has completed, sponsored by W. Dalton Dietrich.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) augmentation of nerve autograft repair in participants with severe peripheral nerve injury (PNI). For humans with acute severe PNI, the hypothesis is that augmentation of nerve autograft repair with ahSCs can potentially enhance axonal regeneration and myelin repair and thus improve functional recovery.
Interventions
- BIOLOGICAL autologous human Schwann cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03999424
The ClinicalTrials.gov registry entry for NCT03999424 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W. Dalton Dietrich, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous human Schwann cells is the first listed.
NCT03999424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03999424 about?
NCT03999424 is a clinical study titled "Autologous Human Schwann Cells in Peripheral Nerve Repair". The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) augmentation of nerve autograft repair in participants with severe peripheral nerve injury (PNI). For humans with acute severe PNI, the hypothesis is that augmentation of nerve autograft repair with ahSCs can p...
What is the current status of trial NCT03999424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-09-24. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT03999424?
The interventions under investigation include: autologous human Schwann cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03999424?
This trial is sponsored by W. Dalton Dietrich, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.